These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 6644555)

  • 21. Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data.
    Hing JP; Woolfrey SG; Greenslade D; Wright PM
    J Pharmacokinet Pharmacodyn; 2001 Oct; 28(5):465-79. PubMed ID: 11768291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Individualization of drug dosage by therapeutic monitoring in plasma and the application of pharmacokinetic principles].
    Klotz U
    J Clin Chem Clin Biochem; 1983 Nov; 21(11):649-58. PubMed ID: 6655441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lithium population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.
    Yukawa E; Nomiyama N; Higuchi S; Aoyama T
    Ther Drug Monit; 1993 Apr; 15(2):75-82. PubMed ID: 8503142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of new measures of nonlinearity to parameter estimation and simulations in individual pharmacokinetic analyses.
    Khinkis L; Crotzer M
    J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):43-52. PubMed ID: 30607795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation.
    Gomeni R
    Comput Biol Med; 1984; 14(1):25-34. PubMed ID: 6546907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.
    Mentré F; Gomeni R
    J Biopharm Stat; 1995 Jul; 5(2):141-58. PubMed ID: 7581424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets.
    Proost JH; Eleveld DJ
    Pharm Res; 2006 Dec; 23(12):2748-59. PubMed ID: 17089202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Problems and pitfalls in estimating average pharmacokinetic parameters.
    Martin E; Moll W; Schmid P; Dettli L
    Eur J Clin Pharmacol; 1984; 26(5):595-602. PubMed ID: 6468475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
    Mu S; Ludden TM
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
    Knights J; Rohatagi S
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies.
    Grasela TH; Antal EJ; Townsend RJ; Smith RB
    Clin Pharmacol Ther; 1986 Jun; 39(6):605-12. PubMed ID: 3709024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
    Staatz CE; Tett SE
    Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.
    Néant N; Gattacceca F; Lê MP; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Solas C
    Eur J Clin Pharmacol; 2018 Apr; 74(4):473-481. PubMed ID: 29374296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimates of the population pharmacokinetic parameters and performance of Bayesian feedback: a sensitivity analysis.
    Vozeh S; Steiner C
    J Pharmacokinet Biopharm; 1987 Oct; 15(5):511-28. PubMed ID: 3694495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pitfalls and valid approaches to pharmacokinetic analysis of mean concentration data following intravenous administration.
    Cocchetto DM; Wargin WA; Crow JW
    J Pharmacokinet Biopharm; 1980 Dec; 8(6):539-52. PubMed ID: 7229907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An analysis program MULTI(ELS) based on extended nonlinear least squares method for microcomputers.
    Yamaoka K; Tanaka H; Okumura K; Yasuhara M; Hori R
    J Pharmacobiodyn; 1986 Feb; 9(2):161-73. PubMed ID: 3754893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming.
    Lindbom L; Ribbing J; Jonsson EN
    Comput Methods Programs Biomed; 2004 Aug; 75(2):85-94. PubMed ID: 15212851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of assay variability on pharmacokinetic parameter estimation.
    Graves DA; Locke CS; Muir KT; Miller RP
    J Pharmacokinet Biopharm; 1989 Oct; 17(5):571-92. PubMed ID: 2614686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of type I error rates for the statistical sub-model in NONMEM.
    Wählby U; Bouw MR; Jonsson EN; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2002 Jun; 29(3):251-69. PubMed ID: 12449498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacodynamic modeling and covariate detection for central neural blockade.
    Schnider TW; Minto CF; Bruckert H; Mandema JW
    Anesthesiology; 1996 Sep; 85(3):502-12. PubMed ID: 8853080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.